Yuan Ping
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Yuan Ping has a total of 312 co-authors. Here are the top co-authors by number of shared publications:
Yuxuan Chen
15 shared publicationsBowen Li
School of Pharmacy, Anhui Medical University, Hefei, 230032, China
14 shared publicationsHonglin Tang
Department of Orthopaedic Surgery, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou 310016, China
13 shared publications- Bowen Li
School of Pharmacy Anhui Medical University Hefei China
11 shared publications Fu Zhang
College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China
11 shared publications- Guping Tang
State Key Laboratory of Swine and Poultry Breeding Industry, College of Animal Science and Technology, Sichuan Agricultural University, Chengdu, China
11 shared publications
Latest Publications
- 28 August 2026
- Published by Elsevier in Nano Today
- Vol. 72
From biodistribution to biological action: Redefining lipid nanoparticle high-throughput screening for therapeutic delivery
- 28 August 2026
- Published by Elsevier in Nano Today
- Vol. 72
From biodistribution to biological action: Redefining lipid nanoparticle high-throughput screening for therapeutic delivery
- 11 July 2026
- Published by Elsevier in Acta Biomaterialia
- Vol. 220, 245-260
A small-molecule self-assembled nano-prodrug for enhanced therapy of cancer stem cell-enriched pancreatic ductal adenocarcinoma
- 11 July 2026
- Published by Elsevier in Acta Biomaterialia
- Vol. 220, 245-260
A small-molecule self-assembled nano-prodrug for enhanced therapy of cancer stem cell-enriched pancreatic ductal adenocarcinoma
- 25 June 2026
- Published by Elsevier in Biomaterials
- Vol. 335, 124407
Versatile hollow Ca2+-phenolic nanoparticles for intracellular delivery of diverse bioactive molecules and CRISPR-Cas9 genome editing
- 25 June 2026
- Published by Elsevier in Biomaterials
- Vol. 335, 124407
Versatile hollow Ca2+-phenolic nanoparticles for intracellular delivery of diverse bioactive molecules and CRISPR-Cas9 genome editing
- 14 May 2026
- Published by Royal Society of Chemistry (RSC) in Biomaterials Science
- Vol. 14 (14) , 3813-3830
Dual-targeting macrophage membrane nanosystem enhances radiotherapy-induced antitumor immunity via synergistic nuclear and mitochondrial DNA damage
A macrophage membrane-coated gold nanosystem enables inflammation-guided tumor targeting and enhances radiotherapy by promoting mitochondrial RNA release and sustained DNA damage, thereby amplifying antitumor immune responses.
- 14 May 2026
- Published by Royal Society of Chemistry (RSC) in Biomaterials Science
- Vol. 14 (14) , 3813-3830
Dual-targeting macrophage membrane nanosystem enhances radiotherapy-induced antitumor immunity via synergistic nuclear and mitochondrial DNA damage
A macrophage membrane-coated gold nanosystem enables inflammation-guided tumor targeting and enhances radiotherapy by promoting mitochondrial RNA release and sustained DNA damage, thereby amplifying antitumor immune responses.
- 6 May 2026
- Published by Elsevier in Biomaterials
- Vol. 334, 124283
A host-guest supramolecular delivery system for heat-inducible RNA editing of survivin for liver cancer therapy
- 6 May 2026
- Published by Elsevier in Biomaterials
- Vol. 334, 124283
A host-guest supramolecular delivery system for heat-inducible RNA editing of survivin for liver cancer therapy
- Open Access
- 23 February 2026
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 16 (5) , 2903-2928
Non-viral delivery of genome-editing tools for treatment of genetic disorders
- 23 February 2026
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 16 (5) , 2903-2928
Open AccessNon-viral delivery of genome-editing tools for treatment of genetic disorders
- 18 February 2026
- Published by Elsevier in Materials Science and Engineering: C
- Vol. 183, 214780
Engineering bacterial outer membrane vesicles synergetically boost superactivated anti-tumor immunity induced by radiotherapy via sustained DNA damage
- 18 February 2026
- Published by Elsevier in Materials Science and Engineering: C
- Vol. 183, 214780
Engineering bacterial outer membrane vesicles synergetically boost superactivated anti-tumor immunity induced by radiotherapy via sustained DNA damage
- Open Access
- 18 February 2026
- Published by Elsevier in Molecular Therapy Oncology
- Vol. 34 (1) , 201144
Engineering systemic oncolytic virotherapy through immune-compatible delivery and programmable tumor cell death
- 18 February 2026
- Published by Elsevier in Molecular Therapy Oncology
- Vol. 34 (1) , 201144
Open AccessEngineering systemic oncolytic virotherapy through immune-compatible delivery and programmable tumor cell death
- Top Cited Papers
- 16 January 2026
- Published by Springer Nature in Nature Cancer
- Vol. 7 (1) , 207-223
Genetic engineering of systemically injectable oncolytic viruses for pyroptosis-accelerated cancer virotherapy
Systemic delivery of oncolytic viruses (OVs) is limited by neutralizing antibodies and poor intratumoral bioavailability. Here we developed genetically engineered, immune-compatible cell membranes expressing a chimeric antigen receptor to cloak OVs, creating a tumor-targeted viral delivery platform (iNV-GOV) that shields virions from immune recognition while guiding them to tumors. The OV payload encodes an N-terminal gasdermin under a heat-shock promoter enabling ultrasound-induced mild hyperthermia to trigger tumor-specific pyroptosis, accelerate oncolysis and promote rapid viral release from lysed tumor cells, thereby amplifying infection of neighboring tumor populations. Following systemic administration, iNV-GOV efficiently targets and infects tumor cells, induces pyroptosis upon ultrasound activation and elicits robust antitumor immunity in patient-derived xenograft models in humanized mice. Collectively, this systemically injectable, tumor-targeted OV platform enables rapid and continuous intratumoral viral propagation and represents a promising strategy for treating a wide range of cancers.
- 16 January 2026
- Published by Springer Nature in Nature Cancer
- Vol. 7 (1) , 207-223
Top Cited PapersGenetic engineering of systemically injectable oncolytic viruses for pyroptosis-accelerated cancer virotherapy
Systemic delivery of oncolytic viruses (OVs) is limited by neutralizing antibodies and poor intratumoral bioavailability. Here we developed genetically engineered, immune-compatible cell membranes expressing a chimeric antigen receptor to cloak OVs, creating a tumor-targeted viral delivery platform (iNV-GOV) that shields virions from immune recognition while guiding them to tumors. The OV payload encodes an N-terminal gasdermin under a heat-shock promoter enabling ultrasound-induced mild hyperthermia to trigger tumor-specific pyroptosis, accelerate oncolysis and promote rapid viral release from lysed tumor cells, thereby amplifying infection of neighboring tumor populations. Following systemic administration, iNV-GOV efficiently targets and infects tumor cells, induces pyroptosis upon ultrasound activation and elicits robust antitumor immunity in patient-derived xenograft models in humanized mice. Collectively, this systemically injectable, tumor-targeted OV platform enables rapid and continuous intratumoral viral propagation and represents a promising strategy for treating a wide range of cancers.
- Open Access
- 31 December 2025
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
In vivo chemogenetic RNA editing of macrophages by bioengineered viruses for sepsis treatment
Sepsis, a life-threatening condition arising from a dysregulated host response to infection, remains a significant clinical challenge with limited therapeutic options. RNA editing presents a promising avenue for modulating gene expression to attenuate the inflammatory cascade characteristic of sepsis. Here, we introduce an approach utilizing chemogenetic activation of CasRx-based RNA editing via bioengineered lentiviruses for the treatment of sepsis. Our strategy involves the targeted delivery of biomineralized lentiviral vectors encoding RNA-editing enzymes and chemogenetic switches to M1 macrophage populations implicated in sepsis pathogenesis. Upon the administration of a small molecule ligand, the chemogenetic switches activate the RNA-editing tool, CasRx, thereby enabling precise and repeated downregulation of NLRP3 mRNA. We demonstrate the efficacy and repeatability of this viral-based approach in mouse models of sepsis, highlighting its potential as a versatile therapeutic strategy for mitigating sepsis-induced inflammation. This study underscores the utility of chemogenetic technologies in harnessing the power of RNA editing for the treatment of sepsis and other inflammatory disorders.
- 31 December 2025
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessIn vivo chemogenetic RNA editing of macrophages by bioengineered viruses for sepsis treatment
Sepsis, a life-threatening condition arising from a dysregulated host response to infection, remains a significant clinical challenge with limited therapeutic options. RNA editing presents a promising avenue for modulating gene expression to attenuate the inflammatory cascade characteristic of sepsis. Here, we introduce an approach utilizing chemogenetic activation of CasRx-based RNA editing via bioengineered lentiviruses for the treatment of sepsis. Our strategy involves the targeted delivery of biomineralized lentiviral vectors encoding RNA-editing enzymes and chemogenetic switches to M1 macrophage populations implicated in sepsis pathogenesis. Upon the administration of a small molecule ligand, the chemogenetic switches activate the RNA-editing tool, CasRx, thereby enabling precise and repeated downregulation of NLRP3 mRNA. We demonstrate the efficacy and repeatability of this viral-based approach in mouse models of sepsis, highlighting its potential as a versatile therapeutic strategy for mitigating sepsis-induced inflammation. This study underscores the utility of chemogenetic technologies in harnessing the power of RNA editing for the treatment of sepsis and other inflammatory disorders.